Key Takeaway: Nurix is focused on developing innovative therapies, particularly in the field of cancer and autoimmune diseases. Their approach involves leveraging novel scientific insights to enhance their portfolio of assets. The article highlights their commitment to protein degradation resources, although specific details about NX-5948's efficacy or clinical progress are not provided.
Price reaction · baseline $25.05 (2024-10-18 close) · 1 other NRIX headline(s) in the window, move may be shared
day 0 close · peak
+1.7%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.